Pavel Martasek

List of Publications by Year
in descending order

247 papers	12,218 citations	28190 55 h-index	30010 103 g-index
265 all docs	265 docs citations	265 times ranked	10090 citing authors

#	Article	IF	Citations
1	Superoxide generation by endothelial nitric oxide synthase: The influence of cofactors. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 9220-9225.	3.3	1,337
2	Dissecting the Interaction between Nitric Oxide Synthase (NOS) and Caveolin. Journal of Biological Chemistry, 1997, 272, 25437-25440.	1.6	731
3	Crystal Structure of Constitutive Endothelial Nitric Oxide Synthase. Cell, 1998, 95, 939-950.	13.5	636
4	Endothelial Nitric Oxide Synthase-Dependent Superoxide Generation from Adriamycinâ€. Biochemistry, 1997, 36, 11293-11297.	1.2	331
5	Plant nitric oxide synthase: a never-ending story?. Trends in Plant Science, 2006, 11, 524-525.	4.3	297
6	Folic Acid Reverts Dysfunction of Endothelial Nitric Oxide Synthase. Circulation Research, 2000, 86, 1129-1134.	2.0	265
7	High-level expression of functional rat neuronal nitric oxide synthase in Escherichia coli.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 8428-8432.	3.3	259
8	The ratio between tetrahydrobiopterin and oxidized tetrahydrobiopterin analogues controls superoxide release from endothelial nitric oxide synthase: an EPR spin trapping study. Biochemical Journal, 2002, 362, 733-739.	1.7	249
9	An Autoinhibitory Control Element Defines Calcium-regulated Isoforms of Nitric Oxide Synthase. Journal of Biological Chemistry, 1997, 272, 29769-29777.	1.6	221
10	Neuronal nitric oxide synthase, a modular enzyme formed by convergent evolution: structure studies of a cysteine thiolateâ€liganded heme protein that hydroxylates Lâ€arginine to produce NO as a cellular signal. FASEB Journal, 1996, 10, 552-558.	0.2	203
11	The Role of Tetrahydrobiopterin in Superoxide Generation from eNOS: Enzymology and Physiological Implications. Free Radical Research, 2003, 37, 121-127.	1.5	190
12	The ratio between tetrahydrobiopterin and oxidized tetrahydrobiopterin analogues controls superoxide release from endothelial nitric oxide synthase: an EPR spin trapping study. Biochemical Journal, 2002, 362, 733.	1.7	186
13	Potent and Selective Inhibition of Neuronal Nitric Oxide Synthase byNÏ‰-Propyl-l-arginine. Journal of Medicinal Chemistry, 1997, 40, 3869-3870.	2.9	185
14	Intrinsic and Extrinsic Modulation of Nitric Oxide Synthase Activity. Chemical Reviews, 2002, 102, 1179-1190.	23.0	185
15	Superoxide anion formation from lucigenin: an electron spin resonance spin-trapping study. FEBS Letters, 1997, 403, 127-130.	1.3	176
16	Tetrahydrobiopterin-dependent Inhibition of Superoxide Generation from Neuronal Nitric Oxide Synthase. Journal of Biological Chemistry, 1999, 274, 26736-26742.	1.6	168
17	Characterization of Bovine Endothelial Nitric Oxide Synthase Expressed inE. coli. Biochemical and Biophysical Research Communications, 1996, 219, 359-365.	1.0	160
18	Endothelial nitric oxide synthase reduces nitrite anions to NO under anoxia. Biochemical and Biophysical Research Communications, 2006, 341, 816-821.	1.0	145

#	Article	IF	Citations
19	Detection of superoxide anion using an isotopically labeled nitrone spin trap: potential biological applications. FEBS Letters, 2000, 473, 58-62.	1.3	143
20	Porphyrinâ"Cyclodextrin Conjugates as a Nanosystem for Versatile Drug Delivery and Multimodal Cancer Therapy. Journal of Medicinal Chemistry, 2010, 53, 128-138.	2.9	117
21	EPR and ENDOR Characterization of Intermediates in the Cryoreduced Oxy-Nitric Oxide Synthase Heme Domain with Bound l-Arginine or NG-Hydroxyarginine. Biochemistry, 2002, 41, 10375-10381.	1.2	116
22	Longâ€term followâ€up of Wilson Disease: natural history, treatment, mutations analysis and phenotypic correlation. Liver International, 2011, 31, 83-91.	1.9	114
23	Crystal Structure of the FAD/NADPH-binding Domain of Rat Neuronal Nitric-oxide Synthase. Journal of Biological Chemistry, 2001, 276, 37506-37513.	1.6	109
24	Reaction of tetrahydrobiopterin with superoxide: EPR-kinetic analysis and characterization of the pteridine radical. Free Radical Biology and Medicine, 2001, 31, 975-985.	1.3	107
25	Structural basis for human NADPH-cytochrome P450 oxidoreductase deficiency. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 13486-13491.	3.3	107
26	Adipocyte Heme Oxygenase-1 Induction Attenuates Metabolic Syndrome in Both Male and Female Obese Mice. Hypertension, 2010, 56, 1124-1130.	1.3	102
27	Minimal Pharmacophoric Elements and Fragment Hopping, an Approach Directed at Molecular Diversity and Isozyme Selectivity. Design of Selective Neuronal Nitric Oxide Synthase Inhibitors. Journal of the American Chemical Society, 2008, 130, 3900-3914.	6.6	101
28	The C Termini of Constitutive Nitric-oxide Synthases Control Electron Flow through the Flavin and Heme Domains and Affect Modulation by Calmodulin. Journal of Biological Chemistry, 2000, 275, 29225-29232.	1.6	99
29	Association of the Glu298Asp Polymorphism in the Endothelial Nitric Oxide Synthase Gene with Essential Hypertension Resistant to Conventional Therapy. Biochemical and Biophysical Research Communications, 2001, 284, 426-430.	1.0	97
30	Involvement of the Reductase Domain of Neuronal Nitric Oxide Synthase in Superoxide Anion Productionâ€. Biochemistry, 1997, 36, 15277-15284.	1.2	90
31	Discovery of Highly Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase by Fragment Hopping. Journal of Medicinal Chemistry, 2009, 52, 779-797.	2.9	86
32	Crystal Structure of Nitric Oxide Synthase Bound to Nitro Indazole Reveals a Novel Inactivation Mechanismâ€. Biochemistry, 2001, 40, 13448-13455.	1.2	78
33	Crystallographic Studies on Endothelial Nitric Oxide Synthase Complexed with Nitric Oxide and Mechanism-Based Inhibitorsâ€. Biochemistry, 2001, 40, 5399-5406.	1.2	78
34	Selective neuronal nitric oxide synthase inhibitors and the prevention of cerebral palsy. Annals of Neurology, 2009, 65, 209-217.	2.8	78
35	Homozygous hereditary coproporphyria caused by an arginine to tryptophane substitution in coproporphyrinogen oxidase and common intragenic polymorphisms. Human Molecular Genetics, 1994, 3, 477-480.	1.4	76
36	NÏ‰-Nitroarginine-Containing Dipeptide Amides. Potent and Highly Selective Inhibitors of Neuronal Nitric Oxide Synthase. Journal of Medicinal Chemistry, 1999, 42, 3147-3153.	2.9	74

#	Article	IF	Citations
37	Mutations in ANTXR1 Cause GAPO Syndrome. American Journal of Human Genetics, 2013, 92, 792-799.	2.6	73
38	Rapid Kinetic Studies of Electron Transfer in the Three Isoforms of Nitric Oxide Synthase. Biochemical and Biophysical Research Communications, 1999, 265, 184-188.	1.0	72
39	Structural basis of hereditary coproporphyria. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14232-14237.	3.3	72
40	Mitochondrial Respiration in the Platelets of Patients with Alzheimerâ€™s Disease. Current Alzheimer Research, 2016, 13, 930-941.	0.7	71
41	Diagnostic exome sequencing in earlyâ€onset Parkinson's disease confirms VPS13C as a rare cause of autosomalâ€recessive Parkinson's disease. Clinical Genetics, 2018, 93, 603-612.	1.0	70
42	Hemin and L-arginine regulation of blood pressure in spontaneous hypertensive rats.. Journal of the American Society of Nephrology: JASN, 1991, 2, 1078-1084.	3.0	68
43	Virtual Histology Evaluation of Atherosclerosis Regression During Atorvastatin and Ezetimibe Administration - HEAVEN Study -. Circulation Journal, 2012, 76, 176-183.	0.7	67
44	Sensitivity of human tissue heme oxygenase to a new synthetic metalloporphyrin. Hepatology, 1989, 10, 365-369.	3.6	66
45	Reduced Amide Bond Peptidomimetics. (4S)-N-(4-Amino-5-[aminoalkyl]aminopentyl)-Nâ€˜-nitroguanidines, Potent and Highly Selective Inhibitors of Neuronal Nitric Oxide Synthase. Journal of Medicinal Chemistry, 2001, 44, 2667-2670.	2.9	66
46	Hereditary Coproporphyria. Seminars in Liver Disease, 1998, 18, 25-32.	1.8	64
47	Cardiac involvement in Wilson disease. Journal of Inherited Metabolic Disease, 2002, 25, 269-277.	1.7	64
48	Glycol Porphyrin Derivatives as Potent Photodynamic Inducers of Apoptosis in Tumor Cells. Journal of Medicinal Chemistry, 2008, 51, 5964-5973.	2.9	64
49	Optical sensing of sulfate by polymethinium salt receptors: colorimetric sensor for heparin. Chemical Communications, 2008, , 1901.	2.2	61
50	Modular Structure of Neuronal Nitric Oxide Synthase: Localization of the Arginine Binding Site and Modulation by Pterin. Biochemical and Biophysical Research Communications, 1995, 210, 288-294.	1.0	59
51	A molecular defect in coproporphyrinogen oxidase gene causing harderoporphyria, a variant form of hereditary coproporphyria. Human Molecular Genetics, 1995, 4, 275-278.	1.4	58
52	Substrate Binding-Induced Changes in the EPR Spectra of the Ferrous Nitric Oxide Complexes of Neuronal Nitric Oxide Synthaseâ€. Biochemistry, 1997, 36, 10987-10992.	1.2	58
53	The C331A Mutant of Neuronal Nitric-Oxide Synthase Is Defective in Arginine Binding. Journal of Biological Chemistry, 1998, 273, 34799-34805.	1.6	58
54	Iron Complexes of Flavonoids-Antioxidant Capacity and Beyond. International Journal of Molecular Sciences, 2021, 22, 646.	1.8	58

#	Article	IF	Citations
55	Coproporphyrinogene oxidase: gene organization and description of a mutation leading to exon 6 skipping. Human Molecular Genetics, 1994, 3, 1325-1330.	1.4	57
56	NOA1 is an essential GTPase required for mitochondrial protein synthesis. Molecular Biology of the Cell, 2011, 22, 1-11.	0.9	57
57	Regulation of heme oxygenase gene expression by cobalt in rat liver and kidney. FEBS Journal, 1990, 192, 577-582.	0.2	55
58	Potent, Highly Selective, and Orally Bioavailable Gem-Difluorinated Monocationic Inhibitors of Neuronal Nitric Oxide Synthase. Journal of the American Chemical Society, 2010, 132, 14229-14238.	6.6	55
59	ENDOR Spectroscopic Evidence for the Position and Structure ofNG-Hydroxy-l-arginine Bound to Holo-Neuronal Nitric Oxide Synthaseâ€. Biochemistry, 1999, 38, 3704-3710.	1.2	52
60	Diminished FAD Binding in the Y459H and V492E Antley-Bixler Syndrome Mutants of Human Cytochrome P450 Reductase. Journal of Biological Chemistry, 2006, 281, 35975-35982.	1.6	50
61	Molecular characterization of homozygous variegate porphyria. Human Molecular Genetics, 1998, 7, 1921-1925.	1.4	49
62	Kinetics of NO Ligation with Nitric-oxide Synthase by Flash Photolysis and Stopped-flow Spectrophotometry. Journal of Biological Chemistry, 1999, 274, 13105-13110.	1.6	49
63	Molecular cloning, sequencing, and functional expression of a cDNA encoding human coproporphyrinogen oxidase.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 3024-3028.	3.3	48
64	Antiâ€inflammatory effects of tetrahydrobiopterin on early rejection in renal allografts: modulation of inducible nitric oxide synthase. FASEB Journal, 2002, 16, 1135-1137.	0.2	48
65	Thermodynamics of Oxidation-Reduction Reactions in Mammalian Nitric-oxide Synthase Isoforms. Journal of Biological Chemistry, 2004, 279, 18759-18766.	1.6	45
66	Exploration of the Active Site of Neuronal Nitric Oxide Synthase by the Design and Synthesis of Pyrrolidinomethyl 2-Aminopyridine Derivatives. Journal of Medicinal Chemistry, 2010, 53, 7804-7824.	2.9	45
67	Kinetics of CO Ligation with Nitric-oxide Synthase by Flash Photolysis and Stopped-flow Spectrophotometry. Journal of Biological Chemistry, 1997, 272, 12523-12528.	1.6	44
68	Selective Inhibition of Neuronal Nitric Oxide Synthase byNÏ‰-Nitroarginine- and Phenylalanine-Containing Dipeptides and Dipeptide Esters. Journal of Medicinal Chemistry, 1997, 40, 2813-2817.	2.9	43
69	Mammalian mitochondrial nitric oxide synthase: Characterization of a novel candidate. FEBS Letters, 2006, 580, 455-462.	1.3	43
70	Isoform-specific differences in the nitrite reductase activity of nitric oxide synthases under hypoxia. Biochemical Journal, 2009, 418, 673-682.	1.7	43
71	[18] Electron spin resonance spin-trapping detection of superoxide generated by neuronal nitric oxide synthase. Methods in Enzymology, 1999, 301, 169-177.	0.4	42
72	Aromatic Reduced Amide Bond Peptidomimetics as Selective Inhibitors of Neuronal Nitric Oxide Synthase. Journal of Medicinal Chemistry, 2003, 46, 1661-1669.	2.9	41

#	Article	IF	Citations
73	Simplified 2-Aminoquinoline-Based Scaffold for Potent and Selective Neuronal Nitric Oxide Synthase Inhibition. Journal of Medicinal Chemistry, 2014, 57, 1513-1530.	2.9	40
74	Aluminium(III) sensing by pyridoxal hydrazone utilising the chelation enhanced fluorescence effect. Journal of Luminescence, 2016, 180, 269-277.	1.5	39
75	Strategy for improved therapeutic efficiency of curcumin in the treatment of gastric cancer. Biomedicine and Pharmacotherapy, 2019, 118, 109278.	2.5	39
76	Oxygen Metabolism by Endothelial Nitric-oxide Synthase. Journal of Biological Chemistry, 2007, 282, 28557-28565.	1.6	38
77	Analogues of 2-aminopyridine-based selective inhibitors of neuronal nitric oxide synthase with increased bioavailability. Bioorganic and Medicinal Chemistry, 2009, 17, 2371-2380.	1.4	38
78	Symmetric Double-Headed Aminopyridines, a Novel Strategy for Potent and Membrane-Permeable Inhibitors of Neuronal Nitric Oxide Synthase. Journal of Medicinal Chemistry, 2011, 54, 2039-2048.	2.9	38
79	Molecular Characterization of Homozygous Variegate Porphyria. Human Molecular Genetics, 1998, 7, 1921-1925.	1.4	37
80	Potent and Selective Double-Headed Thiophene-2-carboximidamide Inhibitors of Neuronal Nitric Oxide Synthase for the Treatment of Melanoma. Journal of Medicinal Chemistry, 2014, 57, 686-700.	2.9	37
81	Synthesis and Evaluation of Peptidomimetics as Selective Inhibitors and Active Site Probes of Nitric Oxide Synthases. Journal of Medicinal Chemistry, 2000, 43, 2938-2945.	2.9	36
82	Recruitment of governing elements for electron transfer in the nitric oxide synthase family. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 15833-15838.	3.3	35
83	Intramolecular hydrogen bonding: A potential strategy for more bioavailable inhibitors of neuronal nitric oxide synthase. Bioorganic and Medicinal Chemistry, 2012, 20, 2435-2443.	1.4	35
84	Electron Paramagnetic Resonance Spectroscopy of the Heme Domain of Inducible Nitric Oxide Synthase:â€‰ Binding of Ligands at the Arginine Site Induces Changes in the Heme Ligation Geometry. Biochemistry, 1996, 35, 7626-7630.	1.2	34
85	Zinc Content of Escherichia coli-expressed Constitutive Isoforms of Nitric-oxide Synthase. Journal of Biological Chemistry, 1999, 274, 14537-14540.	1.6	34
86	Systematic analysis of coproporphyrinogen oxidase gene defects in hereditary coproporphyria and mutation update. , 1999, 13, 44-53.		34
87	Endothelial cell superoxide anion radical generation is not dependent on endothelial nitric oxide synthaseâ€“serine 1179 phosphorylation and endothelial nitric oxide synthase dimer/monomer distribution. Free Radical Biology and Medicine, 2006, 40, 2056-2068.	1.3	33
88	Location of Guanidino Nitrogen ofl-Arginine Substrate Bound to Neuronal Nitric Oxide Synthase (nNOS):Â Determination by Q-band Pulsed ENDOR Spectroscopy. Journal of the American Chemical Society, 1998, 120, 2983-2984.	6.6	32
89	Holoenzyme structures of endothelial nitric oxide synthase â€“ An allosteric role for calmodulin in pivoting the FMN domain for electron transfer. Journal of Structural Biology, 2014, 188, 46-54.	1.3	32
90	Imidazole-containing amino acids as selective inhibitors of nitric oxide synthases. Bioorganic and Medicinal Chemistry, 1999, 7, 1941-1951.	1.4	29

#	Article	IF	Citations
91	Potent and Selective Conformationally Restricted Neuronal Nitric Oxide Synthase Inhibitors. Journal of Medicinal Chemistry, 2004, 47, 703-710.	2.9	29
92	Structure-Based Design and Synthesis ofNÏ‰-Nitro-l-Arginine-Containing Peptidomimetics as Selective Inhibitors of Neuronal Nitric Oxide Synthase. Displacement of the Heme Structural Water. Journal of Medicinal Chemistry, 2007, 50, 2089-2099.	2.9	29
93	Coordination conjugates of therapeutic proteins with drug carriers: A new approach for versatile advanced drug delivery. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5514-5520.	1.0	29
94	HOMOZYGOUS VARIEGATE PORPHYRIA. Lancet, The, 1984, 323, 851.	6.3	28
95	Mapping the active site polarity in structures of endothelial nitric oxide synthase heme domain complexed with isothioureas. Journal of Inorganic Biochemistry, 2000, 81, 133-139.	1.5	28
96	Oxygen Metabolism by Neuronal Nitric-oxide Synthase. Journal of Biological Chemistry, 2007, 282, 7921-7929.	1.6	28
97	Decreased serum antioxidant capacity in patients with Wilson disease is associated with neurological symptoms. Journal of Inherited Metabolic Disease, 2012, 35, 541-548.	1.7	28
98	Properties of human kidney heme oxygenase: Inhibition by synthetic heme analogues and metalloporphyrins. Biochemical and Biophysical Research Communications, 1988, 157, 480-487.	1.0	27
99	Calcium/calmodulin-dependent nitric oxide synthase activity in the CNS of Aplysia californica: Biochemical characterization and link to cGMP pathways. Journal of Inorganic Biochemistry, 2005, 99, 922-928.	1.5	27
100	Potent and selective neuronal nitric oxide synthase inhibitors with improved cellular permeability. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 554-557.	1.0	27
101	Rational Design of Chemical Ligands for Selective Mitochondrial Targeting. Bioconjugate Chemistry, 2013, 24, 1445-1454.	1.8	27
102	Novel 2,4-Disubstituted Pyrimidines as Potent, Selective, and Cell-Permeable Inhibitors of Neuronal Nitric Oxide Synthase. Journal of Medicinal Chemistry, 2015, 58, 1067-1088.	2.9	27
103	Water soluble chromone Schiff base derivatives as fluorescence receptor for aluminium(III). Supramolecular Chemistry, 2017, 29, 1-7.	1.5	27
104	Instability of the Human Cytochrome P450 Reductase A287P Variant Is the Major Contributor to Its Antley-Bixler Syndrome-like Phenotype. Journal of Biological Chemistry, 2016, 291, 20487-20502.	1.6	26
105	Localization of the human coproporphyrinogen oxidase gene to chromosome band 3q12. Human Genetics, 1994, 94, 557-9.	1.8	25
106	Effect of redox-active drugs on superoxide generation from nitric oxide synthases: Biological and toxicological implications. Free Radical Research, 1999, 31, 607-617.	1.5	25
107	Implications for Isoform-selective Inhibitor Design Derived from the Binding Mode of Bulky Isothioureas to the Heme Domain of Endothelial Nitric-oxide Synthase. Journal of Biological Chemistry, 2001, 276, 26486-26491.	1.6	25
108	Structural Basis for Pterin Antagonism in Nitric-oxide Synthase. Journal of Biological Chemistry, 2001, 276, 49133-49141.	1.6	25

#	Article	IF	Citations
109	Structure-Guided Design of Selective Inhibitors of Neuronal Nitric Oxide Synthase. Journal of Medicinal Chemistry, 2013, 56, 3024-3032.	2.9	25
110	Role of mtDNA disturbances in the pathogenesis of Alzheimerâ€™s and Parkinsonâ€™s disease. DNA Repair, 2020, 91-92, 102871.	1.3	25
111	Selective l-nitroargininylaminopyrrolidine and l-nitroargininylaminopiperidine neuronal nitric oxide synthase inhibitors. Bioorganic and Medicinal Chemistry, 2007, 15, 1928-1938.	1.4	24
112	[8] Assay of isoforms of Escherichia coli-expressed nitric oxide synthase. Methods in Enzymology, 1999, 301, 70-78.	0.4	23
113	2-Aminopyridines with a Truncated Side Chain To Improve Human Neuronal Nitric Oxide Synthase Inhibitory Potency and Selectivity. Journal of Medicinal Chemistry, 2015, 58, 5548-5560.	2.9	23
114	Phenyl Ether- and Aniline-Containing 2-Aminoquinolines as Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase. Journal of Medicinal Chemistry, 2015, 58, 8694-8712.	2.9	23
115	Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibition by Optimization of the 2-Aminopyridine-Based Scaffold with a Pyridine Linker. Journal of Medicinal Chemistry, 2016, 59, 4913-4925.	2.9	23
116	RGS2 expression predicts amyloid-Î² sensitivity, MCI and Alzheimerâ€™s disease: genome-wide transcriptomic profiling and bioinformatics data mining. Translational Psychiatry, 2016, 6, e909-e909.	2.4	23
117	Conformationally-restricted arginine analogues as alternative substrates and inhibitors of nitric oxide synthases. Bioorganic and Medicinal Chemistry, 1999, 7, 1097-1104.	1.4	22
118	ENDOR Studies ofl-Arginine andNG-Hydroxy-l-Arginine Bound to All Three Holo-Nitric Oxide Synthase Isozymes. Journal of the American Chemical Society, 2000, 122, 5405-5406.	6.6	22
119	Conformationally Restricted Dipeptide Amides as Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors. Journal of Medicinal Chemistry, 2006, 49, 6254-6263.	2.9	22
120	Mutation analysis of the MECP2 gene in patients of Slavic origin with Rett syndrome: novel mutations and polymorphisms. Journal of Human Genetics, 2007, 52, 342-348.	1.1	22
121	Pentamethinium fluorescent probes: The impact of molecular structure on photophysical properties and subcellular localization. Dyes and Pigments, 2014, 107, 51-59.	2.0	22
122	1H-Pyrazole-1-carboxamidines: new inhibitors of nitric oxide synthase. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 2771-2774.	1.0	21
123	Selective Monocationic Inhibitors of Neuronal Nitric Oxide Synthase. Binding Mode Insights from Molecular Dynamics Simulations. Journal of the American Chemical Society, 2012, 134, 11559-11572.	6.6	21
124	Nitric Oxide Synthase Inhibitors That Interact with Both Heme Propionate and Tetrahydrobiopterin Show High Isoform Selectivity. Journal of Medicinal Chemistry, 2014, 57, 4382-4396.	2.9	21
125	Design, synthesis, and biological testing of potential heme-coordinating nitric oxide synthase inhibitors. Bioorganic and Medicinal Chemistry, 2006, 14, 3185-3198.	1.4	20
126	Analogies and surprising differences between recombinant nitric oxide synthase-like proteins from Staphylococcus aureus and Bacillus anthracis in their interactions with l-arginine analogs and iron ligands. Journal of Inorganic Biochemistry, 2006, 100, 2024-2033.	1.5	20

#	Article	IF	Citations
127	Selective recognition of a saccharide-type tumor marker with natural and synthetic ligands: a new trend in cancer diagnosis. Analytical and Bioanalytical Chemistry, 2010, 398, 1865-1870.	1.9	20
128	Heme-Coordinating Inhibitors of Neuronal Nitric Oxide Synthase. Ironâ^'Thioether Coordination Is Stabilized by Hydrophobic Contacts without Increased Inhibitor Potency. Journal of the American Chemical Society, 2010, 132, 798-806.	6.6	20
129	Mutations of human cytochrome P450 reductase differentially modulate heme oxygenase-1 activity and oligomerization. Archives of Biochemistry and Biophysics, 2011, 513, 42-50.	1.4	20
130	Reductive Activation Of Cr(Vi) By Nitric Oxide Synthase. Chemical Research in Toxicology, 2005, 18, 834-843.	1.7	19
131	Polyhydroxylated Sapphyrins:Â Multisite Non-metallic Catalysts for Activated Phosphodiester Hydrolysis. Journal of the American Chemical Society, 2006, 128, 432-437.	6.6	19
132	Structure-based design, synthesis, and biological evaluation of lipophilic-tailed monocationic inhibitors of neuronal nitric oxide synthase. Bioorganic and Medicinal Chemistry, 2010, 18, 6526-6537.	1.4	19
133	Nitric Oxide Synthases Activation and Inhibition by Metallacarborane-Cluster-Based Isoform-Specific Affectors. Journal of Medicinal Chemistry, 2012, 55, 9541-9548.	2.9	19
134	Peripheral but crucial: A hydrophobic pocket (Tyr706, Leu337, and Met336) for potent and selective inhibition of neuronal nitric oxide synthase. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6258-6261.	1.0	18
135	Hydrophilic, Potent, and Selective 7-Substituted 2-Aminoquinolines as Improved Human Neuronal Nitric Oxide Synthase Inhibitors. Journal of Medicinal Chemistry, 2017, 60, 7146-7165.	2.9	18
136	Molecular analysis of porphobilinogen (PBG) deaminase gene mutations in acute intermittent porphyria: first study in patients of Slavic origin. Scandinavian Journal of Clinical and Laboratory Investigation, 1997, 57, 217-224.	0.6	17
137	Substrate and Substrate Analog Binding to Endothelial Nitric Oxide Synthase:Â Electron Paramagnetic Resonance as an Isoform-Specific Probe of the Binding Mode of Substrate Analogsâ€. Biochemistry, 1997, 36, 11821-11827.	1.2	17
138	Three-fold polyfluoroalkylated amines and isocyanates based on tris(hydroxymethyl)aminomethane (TRIS). Journal of Fluorine Chemistry, 2007, 128, 179-183.	0.9	17
139	Synthesis of Highly Functionalized Fluorinated Porphyrins. Supramolecular Chemistry, 2008, 20, 237-242.	1.5	17
140	Interactions Among Polymorphisms of Susceptibility Loci for Alzheimerâ€™s Disease or Depressive Disorder. Medical Science Monitor, 2018, 24, 2599-2619.	0.5	17
141	Role of the Interdomain Linker Probed by Kinetics of CO Ligation to an Endothelial Nitric Oxide Synthase Mutant Lacking the Calmodulin Binding Peptide (Residues 503â^'517 in Bovine)â€. Biochemistry, 2003, 42, 6500-6506.	1.2	16
142	Combination of two chromophores: Synthesis and PDT application of porphyrinâ€“pentamethinium conjugate. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 82-84.	1.0	16
143	Epigenetic agents in combined anticancer therapy. Future Medicinal Chemistry, 2018, 10, 1113-1130.	1.1	16
144	International Porphyria Molecular Diagnostic Collaborative: an evidence-based database of verified pathogenic and benign variants for the porphyrias. Genetics in Medicine, 2019, 21, 2605-2613.	1.1	16

#	Article	IF	Citations
145	Two Photonâ€Induced Electron Injection From a Nanotrigger in Native Endothelial NOâ€Synthase. ChemPhysChem, 2008, 9, 2325-2331.	1.0	15
146	NO Formation by Neuronal NOâ€Synthase can be Controlled by Ultrafast Electron Injection from a Nanotrigger. ChemBioChem, 2009, 10, 690-701.	1.3	15
147	Identification of six novel P450 oxidoreductase missense variants in Ashkenazi and Moroccan Jewish populations. Pharmacogenomics, 2012, 13, 543-554.	0.6	15
148	Interplay between the APOE Genotype and Possible Plasma Biomarkers in Alzheimerâ€™s Disease. Current Alzheimer Research, 2018, 15, 938-950.	0.7	15
149	ENDOR Spectroscopic Evidence for the Geometry of Binding ofretro-inverso-NÏ‰-Nitroarginine-Containing Dipeptide Amides to Neuronal Nitric Oxide Synthase. Journal of the American Chemical Society, 2000, 122, 7869-7875.	6.6	14
150	Dynamics of NO rebinding to the heme domain of NO synthase-like proteins from bacterial pathogens. Nitric Oxide - Biology and Chemistry, 2006, 15, 312-327.	1.2	14
151	Cyclopropyl- and methyl-containing inhibitors of neuronal nitric oxide synthase. Bioorganic and Medicinal Chemistry, 2013, 21, 1333-1343.	1.4	14
152	Parkin (PARK 2) Mutations Are Rare in Czech Patients with Early-Onset Parkinson's Disease. PLoS ONE, 2014, 9, e107585.	1.1	14
153	Changes of Myocardial Functions in Acute Hepatic Porphyrias. Role of Heme Arginate Administration. Annals of Medicine, 1989, 21, 273-276.	1.5	13
154	Electrophilic polyfluoroalkylating agents based on sulfonate esters. Journal of Fluorine Chemistry, 2008, 129, 235-247.	0.9	13
155	Accessible Chiral Linker to Enhance Potency and Selectivity of Neuronal Nitric Oxide Synthase Inhibitors. ACS Medicinal Chemistry Letters, 2014, 5, 56-60.	1.3	13
156	Hydrazones as novel epigenetic modulators: Correlation between TET 1 protein inhibition activity and their iron(II) binding ability. Bioorganic Chemistry, 2019, 88, 102809.	2.0	13
157	Solid phase extraction and isocratic separation of urinary porphyrins by HPLC. Biomedical Chromatography, 1986, 1, 159-162.	0.8	12
158	The Role of a Conserved Serine Residue within Hydrogen Bonding Distance of FAD in Redox Properties and the Modulation of Catalysis by Ca2+/Calmodulin of Constitutive Nitric-oxide Synthases. Journal of Biological Chemistry, 2006, 281, 34246-34257.	1.6	12
159	Acute intermittent porphyriaâ€ƒâ€“â€ƒimpact of mutations found in the hydroxymethylbilane synthase gene on biochemical and enzymatic protein properties. FEBS Journal, 2009, 276, 2106-2115.	2.2	12
160	Methylated N^{Ï‰}-Hydroxy-<scp>l</scp>-arginine Analogues as Mechanistic Probes for the Second Step of the Nitric Oxide Synthase-Catalyzed Reaction. Biochemistry, 2013, 52, 3062-3073.	1.2	12
161	Novel Mitochondria-targeted Drugs for Cancer Therapy. Mini-Reviews in Medicinal Chemistry, 2021, 21, 816-832.	1.1	12
162	Clinical, biochemical and molecular analyses of six patients with isolated cytochrome c oxidase deficiency due to mutations in the SCO2 gene. Acta Paediatrica, International Journal of Paediatrics, 2004, 93, 1312-7.	0.7	12

#	Article	IF	Citations
163	Synthesis and enzymatic evaluation of 2- and 4-aminothiazole-based inhibitors of neuronal nitric oxide synthase. Beilstein Journal of Organic Chemistry, 2009, 5, 28.	1.3	11
164	Genetic and biochemical study of dual hereditary jaundice: Dubinâ€“Johnson and Gilbertâ€™s syndromes. Haplotyping and founder effect of deletion in ABCC2. European Journal of Human Genetics, 2016, 24, 704-709.	1.4	11
165	Perimidine-based synthetic receptors for determination of copper(II) in water solution. Supramolecular Chemistry, 2018, 30, 218-226.	1.5	11
166	Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design. Pharmaceutics, 2021, 13, 1879.	2.0	11
167	Kinetics of CO and NO Ligation with the Cys331 â†' Ala Mutant of Neuronal Nitric-oxide Synthase. Journal of Biological Chemistry, 2001, 276, 4733-4736.	1.6	10
168	Supramolecular approach for target transport of photodynamic anticancer agents. Supramolecular Chemistry, 2012, 24, 106-116.	1.5	10
169	Chiral linkers to improve selectivity of double-headed neuronal nitric oxide synthase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5674-5679.	1.0	10
170	Specific ligands based on TrÃ¶gerâ€™s base derivatives for the recognition of glycosaminoglycans. Dyes and Pigments, 2016, 134, 212-218.	2.0	10
171	Human coproporphyrinogen oxidase. Biochemical characterization of recombinant normal and R231W mutated enzymes expressed in E. coli as soluble, catalytically active homodimers. Cellular and Molecular Biology, 1997, 43, 47-58.	0.3	10
172	Chromophoric Binaphthyl Derivatives. Organic Letters, 2005, 7, 3661-3664.	2.4	9
173	Branched polyfluorinated triflateâ€"An easily available polyfluoroalkylating agent. Journal of Fluorine Chemistry, 2006, 127, 386-390.	0.9	9
174	Characterization of two missense variants in the hydroxymethylbilane synthase gene in the Israeli population, which differ in their associations with acute intermittent porphyria. Molecular Genetics and Metabolism, 2008, 94, 343-346.	0.5	9
175	Correlation between biochemical findings, structural and enzymatic abnormalities in mutated HMBS identified in six Israeli families with acute intermittent porphyria. Blood Cells, Molecules, and Diseases, 2009, 42, 167-173.	0.6	9
176	Effects of high tidal volume mechanical ventilation on production of cytokines, iNOS, and MIP-1Î² proteins in pigs. Experimental Lung Research, 2013, 39, 1-8.	0.5	9
177	Eight mutations including 5 novel ones in the COL1A1 gene in Czech patients with osteogenesis imperfecta. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2016, 160, 442-447.	0.2	9
178	Titration of Low Kd Binding Sites: Binding of Arginine Analogs to Nitric Oxide Synthases. Nitric Oxide - Biology and Chemistry, 2001, 5, 442-452.	1.2	8
179	Improved Synthesis of Chiral Pyrrolidine Inhibitors and Their Binding Properties to Neuronal Nitric Oxide Synthase. Journal of Medicinal Chemistry, 2011, 54, 6399-6403.	2.9	8
180	Immunomagnetic molecular probe with UHPLCâ€"MS/MS: A promising way for reliable bronchial asthma diagnostics based on quantification of cysteinyl leukotrienes. Journal of Pharmaceutical and Biomedical Analysis, 2013, 81-82, 108-117.	1.4	8

#	Article	IF	Citations
181	Striking Antitumor Activity of a Methinium System with Incorporated Quinoxaline Unit Obtained by Spontaneous Cyclization. ChemBioChem, 2015, 16, 555-558.	1.3	8
182	MECP2 mutations in Czech patients with Rett syndrome and Rett-like phenotypes: novel mutations, genotypeâ€“phenotype correlations and validation of high-resolution melting analysis for mutation scanning. Journal of Human Genetics, 2016, 61, 617-625.	1.1	8
183	Benzoisothiazole-1,1-dioxide-based synthetic receptor for zinc ion recognition in aqueous medium and its interaction with nucleic acids. Supramolecular Chemistry, 2019, 31, 19-27.	1.5	8
184	EPR spin trapping of superoxide from nitric oxide synthase. Analusis - European Journal of Analytical Chemistry, 2000, 28, 487-492.	0.4	8
185	N -acetyl cysteine averted liver transplantation in a patient with liver failure caused by erythropoietic protoporphyria. Liver Transplantation, 2009, 15, 352-354.	1.3	7
186	Synthesis of unsymmetric cyanine dye via merocyanine and their interaction with DNA. Collection of Czechoslovak Chemical Communications, 2009, 74, 1081-1090.	1.0	7
187	In search of potent and selective inhibitors of neuronal nitric oxide synthase with more simple structures. Bioorganic and Medicinal Chemistry, 2013, 21, 5323-5331.	1.4	7
188	Combination of chiral linkers with thiophenecarboximidamide heads to improve the selectivity of inhibitors of neuronal nitric oxide synthase. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4504-4510.	1.0	7
189	New method for recognition of sterol signalling molecules: Methinium salts as receptors for sulphated steroids. Steroids, 2015, 94, 15-20.	0.8	7
190	A Cyclic Pentamethinium Salt Induces Cancer Cell Cytotoxicity through Mitochondrial Disintegration and Metabolic Collapse. International Journal of Molecular Sciences, 2019, 20, 4208.	1.8	7
191	Pentamethinium salts as ligands for cancer: Sulfated polysaccharide co-receptors as possible therapeutic target. Bioorganic Chemistry, 2019, 82, 74-85.	2.0	7
192	Changes of BMI, steroid metabolome and psychopathology in patients with anorexia nervosa during hospitalization. Steroids, 2020, 153, 108523.	0.8	7
193	Synthesis and Evaluation of Dipeptide Amides Containing N^{Ï‰}-Nitroarginine and D-2, 4-Diaminobutyric Acids as Inhibitors of Neuronal Nitric Oxide Synthase. Journal of Enzyme Inhibition and Medicinal Chemistry, 2001, 16, 233-239.	0.5	6
194	Superoxide Generation from Nitric Oxide Synthase. , 2005, , 75-91.		6
195	Hydroxyl-terminated peptidomimetic inhibitors of neuronal nitric oxide synthase. Bioorganic and Medicinal Chemistry, 2006, 14, 3681-3690.	1.4	6
196	Hydroxyethylene isosteres of selective neuronal nitric oxide synthase inhibitors. Bioorganic and Medicinal Chemistry, 2007, 15, 6096-6108.	1.4	6
197	Parkin mutations and phenotypic features in Czech patients with early-onset Parkinson's disease. Neuroendocrinology Letters, 2010, 31, 187-92.	0.2	6
198	Porphyrinogens in Plasma. Archives of Dermatology, 1982, 118, 624.	1.7	5

#	Article	IF	Citations
199	Detection of DNA variations in the polymorphic hydroxymethylbilane synthase gene by high-resolution melting analysis. Analytical Biochemistry, 2009, 395, 41-48.	1.1	5
200	Genetic variations in NADPH-CYP450 oxidoreductase in a Czech Slavic cohort. Pharmacogenomics, 2015, 16, 205-215.	0.6	5
201	Highly selective mitochondrial probes based on fluorinated pentamethinium salts: On two-photon properties and microscopic applications. Dyes and Pigments, 2020, 172, 107802.	2.0	5
202	Coumarin TrÃ¶gerâ€™s base derivatives with cyanine substitution as selective and sensitive fluorescent lysosomal probes. Bioorganic Chemistry, 2020, 94, 103447.	2.0	5
203	PPO-Inhibiting Herbicides and Structurally Relevant Schiff Bases: Evaluation of Inhibitory Activities against Human Protoporphyrinogen Oxidase. Processes, 2021, 9, 383.	1.3	5
204	A novel sorbent for chromatographic separations: A silica matrix modified with nonâ€covalently bonded tetrakis(Î²â€cyclodextrin)â€“porphyrin conjugates. Journal of Separation Science, 2013, 36, 2072-2080.	1.3	4
205	Methinium colorimetric sensors for the determination of cholesterol sulfate in an aqueous medium. Sensors and Actuators B: Chemical, 2017, 245, 1032-1038.	4.0	4
206	Anticancer pentamethinium salt is a potent photosensitizer inducing mitochondrial disintegration and apoptosis upon red light illumination. Journal of Photochemistry and Photobiology B: Biology, 2020, 209, 111939.	1.7	4
207	Spectroscopic study of in situâ€formed metallocomplexes of proton pump inhibitors in water. Chemical Biology and Drug Design, 2021, 97, 305-314.	1.5	4
208	Resin Hemoperfusion in Hepatic Porphyrias. Artificial Organs, 1985, 9, 169-172.	1.0	3
209	Porphyria Cutanea Tarda Manifestation and Therapy. Annals of the New York Academy of Sciences, 1987, 514, 335-336.	1.8	3
210	APOE Îµ4: A Potential Modulation Factor in Rett Syndrome. Journal of Child Neurology, 2010, 25, 546-550.	0.7	3
211	Design, Synthesis, Selective Recognition Properties and Targeted Drug Delivery Application. Handbook of Porphyrin Science, 2014, , 1-75.	0.3	3
212	Optical probes and sensors as perspective tools in epigenetics. Bioorganic and Medicinal Chemistry, 2017, 25, 2295-2306.	1.4	3
213	Formaldehyde Reacts with Amino Acids and Peptides with a Potential Role in Acute Methanol Intoxication. Journal of Analytical Toxicology, 2020, 44, 880-885.	1.7	3
214	Porphyrinogens in Urine in Various Types of Porphyrias. Clinical Chemistry and Laboratory Medicine, 1982, 20, 113-7.	1.4	2
215	Czech bibliometric system fosters mediocre research. Nature, 2009, 460, 1079-1079.	13.7	2
216	Methyl Gallate as the Framework for the Construction of Fluorous Building Blocks. Synthetic Communications, 2009, 40, 247-256.	1.1	2

#	Article	IF	Citations
217	Dimethinium Heteroaromatic Salts as Building Blocks for Dualâ€Fluorescence Intracellular Probes. ChemPhotoChem, 2017, 1, 442-450.	1.5	2
218	Influence of the lung mechanical ventilation with injurious parameters on 7-ketocholesterol synthesis in Sus Scrofa. BMB Reports, 2010, 43, 257-262.	1.1	2
219	Heterologous expression and purification of recombinant human protoporphyrinogen oxidase IX: A comparative study. PLoS ONE, 2021, 16, e0259837.	1.1	2
220	Hepatoerythropoietic Porphyria Caused by a Novel Homoallelic Mutation in Uroporphyrinogen Decarboxylase Gene in Egyptian Patients. Folia Biologica, 2015, 61, 219-26.	0.8	2
221	Molecular Diagnostics of Copper-Transporting Protein Mutations Allows Early Onset Individual Therapy of Menkes Disease. Folia Biologica, 2017, 63, 165-173.	0.8	2
222	Hemoperfusion through polymer-coated adsorbents for metabolic disorders in liver disease. Die Makromolekulare Chemie, 1985, 9, 81-84.	1.1	1
223	Prokaryotic Expression, Purification, Characterization of Intact Modular Constructs of Neuronal Nitric Oxide Synthase. Methods in Neurosciences, 1996, 31, 140-151.	0.5	1
224	ASSOCIATION OF ENDOTHELIAL NITRIC-OXIDE SYNTHASE GENE POLYMORPHISM WITH HYPERTENSION. Journal of Hypertension, 2000, 18, S147.	0.3	1
225	Competition and binding of arginine, imidazole, and aminoguanidine to endothelial nitric oxide synthase: aminoguanidine is a poor model for substrate, intermediate, and arginine analog inhibitor binding. Nitric Oxide - Biology and Chemistry, 2003, 8, 149-154.	1.2	1
226	Lichen sclerosus et atrophicus-like skin lesions in a patient carrying a novel hydroxymethylbilane synthase mutation. Blood Cells, Molecules, and Diseases, 2010, 45, 176-179.	0.6	1
227	Molecular characterization of a novel His333Arg variant of human protoporphyrinogen oxidase IX. Biochemical and Biophysical Research Communications, 2022, 588, 182-186.	1.0	1
228	A Novel Mutation in the FECH Gene in a Czech Family with Erythropoietic Protoporphyria and a Population Study of IVS3-48C Variant Contributing to the Disease. Folia Biologica, 2015, 61, 227-32.	0.8	1
229	Induction of Acute Attack in Acute Hepatic Porphyrias Experiences with Diagnosis and Therapy over Thirty Years. Annals of the New York Academy of Sciences, 1987, 514, 342-344.	1.8	0
230	Porphyrinostatic effect of isonicotinic Acid hydrazide on porphyric chick embryo and yeast. International Journal of Biochemistry & Cell Biology, 1988, 20, 1281-1283.	0.8	0
231	In frame deletion of glycin 390 in coproporphyrinogen oxidase gene as a cause of hereditary coproporphyria. Journal of Hepatology, 2001, 34, 223-224.	1.8	0
232	559 CNS impairment in the children from patients with Wilson disease. Journal of Hepatology, 2004, 40, 164.	1.8	0
233	Corrigendum to â€œMammalian mitochondrial nitric oxide synthase: Characterization of a novel candidateâ€•[FEBS Lett. 580 (2006) 455-462]. FEBS Letters, 2007, 581, 2072-2073.	1.3	0
234	P49. Only eNOS among the NOS isoforms is a nitrite reductase under hypoxia. Nitric Oxide - Biology and Chemistry, 2008, 19, 54.	1.2	0

#	Article	IF	Citations
235	888 IMPROVEMENT OF LIVER DYSFUNCTION AFTER TREATMENT WITH N-ACETYL CYSTEINE IN PATIENT WITH ERYTHROPOIETIC PROTOPORHYRIA. Journal of Hepatology, 2008, 48, S333.	1.8	0
236	Prediction of coronary vessel involvement on the basis of atherosclerosis risk factor analysis. Bratislava Medical Journal, 2013, 114, 413-417.	0.4	0
237	Supramolecular Approach in Photodynamic and Photothermal Therapies. , 2017, , 421-440.		0
238	Reaction Pathways and Stoichiometry of Nitric Oxide Synthase. FASEB Journal, 2006, 20, A41.	0.2	0
239	Molecular pathology of copper metabolism: Mutation screening in the ATP7A gene in Czech patients with Menkes disease â€•identification of two novel mutations. FASEB Journal, 2006, 20, A98.	0.2	0
240	Conformational changes in Nitric Oxide Synthase Isoforms Under High Hydrostatic Pressure. FASEB Journal, 2006, 20, A905.	0.2	0
241	Mutation analysis of the MECP2 gene in patients with Rett syndrome. FASEB Journal, 2006, 20, A70.	0.2	0
242	Molecular pathology of heme biosynthesis. Porphobilinogen deaminase (PBGD): Novel mutations in Czech and Slovak patients with acute intermittent porphyria (AIP). FASEB Journal, 2006, 20, .	0.2	0
243	Oxygen: The Overlooked Substrate for Nitric Oxide Synthases. FASEB Journal, 2007, 21, .	0.2	0
244	Defects in ATP Dependent Canalicular Transporter ABCC2. Mutation Study of ABCC2 Gene in a Large Family with Dubinâ€Johnson syndrome.. FASEB Journal, 2008, 22, 813.6.	0.2	0
245	Pigments from Filamentous Ascomycetes for Combination Therapy. Current Medicinal Chemistry, 2019, 26, 3812-3834.	1.2	0
246	Stress perception and (GT)n repeat polymorphism in haem oxygenase 1 promoter are both risk factors in development of eating disorders. Folia Biologica, 2013, 59, 233-9.	0.8	0
247	Novel CDKL5 Mutations in Czech Patients with Phenotypes of Atypical Rett Syndrome and Early-Onset Epileptic Encephalopathy. Folia Biologica, 2016, 62, 67-74.	0.8	0